These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34155340)

  • 21. Prospective close monitoring of the effect of vascular-targeted photodynamic therapy and high intensity focused ultrasound of localized prostate cancer by multiparametric magnetic resonance imaging.
    Solyanik O; Chaloupka M; Clevert DA; Schmidt VF; Ingenerf M; Kazmierczak P; Stief CG; Ricke J; Apfelbeck M
    World J Urol; 2024 Aug; 42(1):462. PubMed ID: 39088086
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Positron Emission Tomography/Computed Tomography with Gallium-68-labeled Prostate-specific Membrane Antigen Detects Relapse After Vascular-targeted Photodynamic Therapy in a Prostate Cancer Model.
    Alvim R; Nagar K; Das S; Lebdai S; Wong N; Somma A; Hughes C; Thomas J; Monette S; Scherz A; Kim K; Grimm J; Coleman JA
    Eur Urol Focus; 2021 Mar; 7(2):472-478. PubMed ID: 31227464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Feasibility, safety, and efficacy of salvage radical prostatectomy after Tookad® Soluble focal treatment for localized prostate cancer.
    Lebdai S; Villers A; Barret E; Nedelcu C; Bigot P; Azzouzi AR
    World J Urol; 2015 Jul; 33(7):965-71. PubMed ID: 25614256
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The addition of AG-013736 to fractionated radiation improves tumor response without functionally normalizing the tumor vasculature.
    Fenton BM; Paoni SF
    Cancer Res; 2007 Oct; 67(20):9921-8. PubMed ID: 17942924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Choroidal neovascularization reduced by targeted drug delivery with cationic liposome-encapsulated paclitaxel or targeted photodynamic therapy with verteporfin encapsulated in cationic liposomes.
    Gross N; Ranjbar M; Evers C; Hua J; Martin G; Schulze B; Michaelis U; Hansen LL; Agostini HT
    Mol Vis; 2013; 19():54-61. PubMed ID: 23335851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expanding indication of padeliporfin (WST11) vascular-targeted photodynamic therapy: results of prostate cancer Latin-American multicenter study.
    Rodriguez-Rivera JA; Rodriguez-Lay R; Zegarra-Montes L; Benzaghou F; Gaillac B; Azzouzi AR; Reis LO; Palma P
    Actas Urol Esp (Engl Ed); 2018 Dec; 42(10):632-638. PubMed ID: 29699883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of vessel-targeting agents and fractionated radiation therapy: the role of the SDF-1/CXCR4 pathway.
    Chen FH; Fu SY; Yang YC; Wang CC; Chiang CS; Hong JH
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):777-84. PubMed ID: 23601898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vascular targeted photodynamic therapy with TOOKAD® Soluble (WST11) in localized prostate cancer: efficiency of automatic pre-treatment planning.
    Betrouni N; Boukris S; Benzaghou F
    Lasers Med Sci; 2017 Aug; 32(6):1301-1307. PubMed ID: 28569345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current evidence for focal laser ablation and vascular-targeted photodynamic therapy for localized prostate cancer: review of literature published in the last 2 years.
    Candela L; Kasraeian A; Barret E
    Curr Opin Urol; 2022 Mar; 32(2):192-198. PubMed ID: 35013079
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vascular targeted photochemotherapy using padoporfin and padeliporfin as a method of the focal treatment of localised prostate cancer - clinician's insight.
    Bugaj AM
    World J Methodol; 2016 Mar; 6(1):65-76. PubMed ID: 27019798
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cryoablation, high-intensity focused ultrasound, irreversible electroporation, and vascular-targeted photodynamic therapy for prostate cancer: a systemic review and meta-analysis.
    Guo RQ; Guo XX; Li YM; Bie ZX; Li B; Li XG
    Int J Clin Oncol; 2021 Mar; 26(3):461-484. PubMed ID: 33387088
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Re: TOOKAD® soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer.
    Cadeddu JA
    J Urol; 2014 May; 191(5):1290. PubMed ID: 24745491
    [No Abstract]   [Full Text] [Related]  

  • 33. Re: TOOKAD ® soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer.
    Taneja SS
    J Urol; 2014 Apr; 191(4):983-4. PubMed ID: 24703118
    [No Abstract]   [Full Text] [Related]  

  • 34. [Treatment of localized prostate cancer by vascular-targeted photodynamic therapy with WST11].
    Lebdai S; Martin F; Bigot P; Azzouzi AR
    Prog Urol; 2014 Nov; 24(14):911-4. PubMed ID: 25195031
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nanoparticle delivered vascular disrupting agents (VDAs): use of TNF-alpha conjugated gold nanoparticles for multimodal cancer therapy.
    Shenoi MM; Iltis I; Choi J; Koonce NA; Metzger GJ; Griffin RJ; Bischof JC
    Mol Pharm; 2013 May; 10(5):1683-94. PubMed ID: 23544801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate gland: MR imaging appearance after vascular targeted photodynamic therapy with palladium-bacteriopheophorbide.
    Haider MA; Davidson SR; Kale AV; Weersink RA; Evans AJ; Toi A; Gertner MR; Bogaards A; Wilson BC; Chin JL; Elhilali M; Trachtenberg J
    Radiology; 2007 Jul; 244(1):196-204. PubMed ID: 17507719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models.
    Passer BJ; Cheema T; Wu S; Wu CL; Rabkin SD; Martuza RL
    Cancer Gene Ther; 2013 Jan; 20(1):17-24. PubMed ID: 23138870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potentiating vascular-targeted photodynamic therapy through CSF-1R modulation of myeloid cells in a preclinical model of prostate cancer.
    Lebdai S; Gigoux M; Alvim R; Somma A; Nagar K; Azzouzi AR; Cussenot O; Merghoub T; Wolchok JD; Scherz A; Kim K; Coleman J
    Oncoimmunology; 2019; 8(6):e1581528. PubMed ID: 31069149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Morbidity of focal therapy in the treatment of localized prostate cancer.
    Barret E; Ahallal Y; Sanchez-Salas R; Galiano M; Cosset JM; Validire P; Macek P; Durand M; Prapotnich D; Rozet F; Cathelineau X
    Eur Urol; 2013 Apr; 63(4):618-22. PubMed ID: 23265382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histopathology of prostate tissue after vascular-targeted photodynamic therapy for localized prostate cancer.
    Eymerit-Morin C; Zidane M; Lebdai S; Triau S; Azzouzi AR; Rousselet MC
    Virchows Arch; 2013 Oct; 463(4):547-52. PubMed ID: 23948957
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.